{"id":"W2793364080","doi":"10.1001/jamaoncol.2018.0013","title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer","year":2018,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1812,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Genentech; Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; Sirtex Medical; Five Prime Therapeutics; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Yakult Honsha; Sanofi; Kyowa Hakko Kirin; MacroGenics; Arog Pharmaceuticals; Pfizer; Incyte; Halozyme; Amgen; Celgene; Bristol-Myers Squibb; AstraZeneca; Chugai Pharmaceutical; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Internal medicine; Cancer; Cohort; Response Evaluation Criteria in Solid Tumors; Progressive disease; Clinical endpoint; Gastroenterology; Surgery; Disease; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001442464,0.000264582,0.0007563896,0.0002607295,0.0003257105,0.0004973903,0.0002006654,0.0004387025,0.001054125],"category_scores_gemma":[0.001970434,0.0001788248,0.0005807354,0.0003536081,0.0002655701,0.0004934698,0.0001983477,0.0005340773,0.0002255819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004256133,"about_ca_system_score_gemma":0.0004201813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000359816,"about_ca_topic_score_gemma":0.0009622854,"domain_scores_codex":[0.9995108,0.0002138421,0.00005532829,0.00008640685,0.00009734672,0.00003632735],"domain_scores_gemma":[0.9988059,0.0002778747,0.0005954297,0.00005394374,0.00007551801,0.0001914068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.06281703,0.002313447,0.8667809,0.0003578341,0.001432247,0.0004613652,0.0001939721,0.001026287,0.01290846,0.00004656214,0.001039183,0.0506228],"study_design_scores_gemma":[0.008330817,0.04299608,0.9403614,0.00007138257,0.0007037877,0.001382301,0.0001388675,0.00169832,0.002055922,0.00006328984,0.002169608,0.00002827216],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"editorial","genre_scores_codex":[0.9977991,0.001464203,0.00007355161,0.00006236164,0.000009743126,0.00004169222,0.0001712298,0.000004789498,0.0003732391],"genre_scores_gemma":[0.9989791,0.0003720772,0.0001239847,0.00009152967,0.000022067,0.00003224416,0.0002800233,0.000001455646,0.00009750784],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.001442464,"threshold_uncertainty_score":0.00762856,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008114240074526269,"score_gpt":0.2647737009068763,"score_spread":0.25665946083235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}